

Estimated Vaccination Coverage* With Selected Vaccines and Doses Among Adolescents Aged 13-17 Years[†] by Age at Interview - National Immunization Survey-Teen, 2014

Vaccines	Age at Interview (years)					2014
	13 (n = 4,292) % (95% CI)	14 (n = 4,329) % (95% CI)	15 (n = 4,143) % (95% CI)	16 (n = 4,215) % (95% CI)	17 (n = 3,848) % (95% CI)	(n = 20,827) % (95% CI)
Td or Tdap						
≥1 dose Td/Tdap [§]	88.7(±2.0)	90.9(±1.5)	90.3(±1.6)	90.0(±1.8)	89.0(±1.9)	89.8(±0.8)
≥1 dose Tdap [¶]	87.5(±2.1)	89.1(±1.6)	88.3(±1.9)	86.9(±2.1)	86.3(±2.0)	87.6(±0.9)
≥1 dose MenACWY**	78.0(±2.5)	81.0(±2.1)	79.2(±2.5)	79.4(±2.5)	78.8(±2.5)	79.3(±1.1)
≥2 doses MenACWY	--	--	--	--	28.5(±2.8) ^{††}	--
HPV^{§§} vaccine coverage by doses						
FEMALE						
≥1 dose	51.1(±4.1)	56.6(±3.9)	61.0(±4.3)	64.4(±4.1)	66.5(±4.4)	60.0(±1.9)
≥2 doses	40.1(±4.0)	46.4(±4.0)	51.6(±4.3)	55.7(±4.2)	57.6(±4.7)	50.3(±1.9)
≥3 doses	26.2(±3.6)	35.9(±3.9)	41.2(±4.2)	43.8(±4.1)	51.0(±4.7)	39.7(±1.9)
MALE						
≥1 dose	38.9(±4.2)	42.6(±4.0)	45.7(±4.1)	40.0(±4.0)	41.8(±4.1)	41.7(±1.8)
≥2 doses	27.1(±3.9)	30.9(±3.8)	35.8(±4.1)	31.2(±3.8)	32.6(±4.0)	31.4(±1.7)
≥3 doses	16.2(±3.3)	20.9(±3.5)	24.9(±4.0)	22.9(±3.5)	23.3(±3.7)	21.6(±1.6)
HPV 3-dose series completion^{††}						
Females	56.1(±6.3)	66.8(±5.2)	70.3(±5.0)	70.8(±5.2)	78.3(±5.4)	69.3(±2.4)
Males	47.1(±7.6)	56.6(±6.6)	58.1(±6.6)	64.7(±6.1)	61.7(±6.6)	57.8(±3.0)
≥2 doses MMR***	90.2(±1.8)	91.1(±1.6)	91.2(±1.6)	90.2(±1.9)	90.9(±1.6)	90.7(±0.8)
≥3 doses Hepatitis B	91.3(±1.8)	91.7(±1.5)	92.5(±1.4)	90.2(±2.0)	91.4(±1.5)	91.4(±0.7)
Varicella						
History of varicella disease ^{†††}	13.7(±2.0)	17.8(±2.4)	20.2(±2.4)	24.2(±2.6)	29.3(±2.8)	21.0(±1.1)
≥1 dose vaccine if had no history of disease	95.6(±1.3)	95.7(±1.2)	95.6(±1.1)	95.1(±1.2)	93.6(±1.5)	95.2(±0.6)
≥2 doses vaccine if had no history of disease	83.1(±2.4)	81.9(±2.3)	81.1(±2.6)	81.0(±2.6)	77.1(±3.1)	81.0(±1.2)
History of disease or received ≥2 doses varicella vaccine	85.4(±2.1)	85.1(±1.9)	85.0(±2.1)	85.6(±2.0)	83.8(±2.3)	85.0(±0.9)

Abbreviations: Td = tetanus toxoid, reduced diphtheria toxoid; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis; MenACWY = meningococcal conjugate; HPV = human papilloma virus; MMR = measles, mumps, and rubella; CI = confidence interval

* Estimate presented as point estimate (%) ± 95% CI.

[†] Adolescents in the 2014 NIS-Teen were born January 1996 through February 2002. Vaccination coverage estimates include only adolescents who had adequate provider-reported immunization records. National estimates do not include adolescents living in Puerto Rico (n=230).

[§] ≥1 dose of Td or Tdap vaccine since age 10 years.

[¶] ≥1 dose of Tdap vaccine since age 10 years.

** ≥1 dose of MenACWY or meningococcal-unknown type vaccine.

^{††} ≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents who were 17 years of age at interview. Does not include adolescents who received only 1 dose of MenACWY vaccine at or after age 16 years.

^{§§} HPV vaccine, either quadrivalent (4vHPV) or bivalent (2vHPV). While only 4vHPV was recommended for use in males in 2014, some could have received 2vHPV. Percentages reported among females (n = 10,084) and males (n = 10,743). Some adolescents might have received more than the 3 recommended HPV vaccine doses.

^{†††} Percent of adolescents who received ≥ 3 HPV doses among those who had ≥ 1 HPV vaccine dose with at least 24 weeks between the first dose and the interview date. The denominator for this calculation was limited to females (n = 5,703) and males (n = 3,935) who received their first HPV dose and had enough time to receive the third HPV dose.

*** ≥2 doses of measles, mumps, and rubella vaccine.

^{†††} By parent/guardian report or provider records.